Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roxana Rustomjee

Showing results (21-30 of 44) with videos related to

Pageof 5
Sort By:
Antimicrobial Agents and Chemotherapy|January 23, 2020
<i>N</i>-Acetyltransferase 2 Genotypes among Zulu-Speaking South Africans and Isoniazid and <i>N</i>-Acetyl-Isoniazid Pharmacokinetics during Antituberculosis TreatmentThuli Mthiyane, James Millard, John Adamson, et al.
The Lancet. Infectious Diseases|April 26, 2011
Use of a WHO-recommended algorithm to reduce mortality in seriously ill patients with HIV infection and smear-negative pulmonary tuberculosis in South Africa: an observational cohort studyTimothy H Holtz, Gaëtan Kabera, Thuli Mthiyane, et al.
Vaccines|March 26, 2022
Vaccine Licensure in the Absence of Human Efficacy DataCourtney L Finch, Christian Martinez, Elizabeth Leffel, et al.
The Journal of Infectious Diseases|November 8, 2017
Drivers of Tuberculosis TransmissionBarun Mathema, Jason R Andrews, Ted Cohen, et al.
Antimicrobial Agents and Chemotherapy|March 14, 2012
Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelinesHelen McIlleron, Roxana Rustomjee, Mahnaz Vahedi, et al.
The Journal of Infectious Diseases|November 8, 2017
Research Roadmap for Tuberculosis Transmission Science: Where Do We Go From Here and How Will We Know When We're There?Sara C Auld, Anne G Kasmar, David W Dowdy, et al.
Plos One|May 19, 2012
Effect of standard tuberculosis treatment on plasma cytokine levels in patients with active pulmonary tuberculosisCatherine Riou, Blas Perez Peixoto, Lindi Roberts, et al.
American Journal of Respiratory and Critical Care Medicine|April 5, 2005
The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosisFrik A Sirgel, P Bernard Fourie, Peter R Donald, et al.
The Lancet. Infectious Diseases|December 18, 2018
Advances in the understanding of Mycobacterium tuberculosis transmission in HIV-endemic settingsJulian S Peters, Jason R Andrews, Mark Hatherill, et al.
The Lancet. Infectious Diseases|April 3, 2016
Tuberculosis--advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkersRobert S Wallis, Markus Maeurer, Peter Mwaba, et al.
Pageof 5

Showing results (21-30 of 44) with videos related to

Sort By:
Pageof 5
Antimicrobial Agents and Chemotherapy|January 23, 2020
<i>N</i>-Acetyltransferase 2 Genotypes among Zulu-Speaking South Africans and Isoniazid and <i>N</i>-Acetyl-Isoniazid Pharmacokinetics during Antituberculosis TreatmentThuli Mthiyane, James Millard, John Adamson, et al.
The Lancet. Infectious Diseases|April 26, 2011
Use of a WHO-recommended algorithm to reduce mortality in seriously ill patients with HIV infection and smear-negative pulmonary tuberculosis in South Africa: an observational cohort studyTimothy H Holtz, Gaëtan Kabera, Thuli Mthiyane, et al.
Vaccines|March 26, 2022
Vaccine Licensure in the Absence of Human Efficacy DataCourtney L Finch, Christian Martinez, Elizabeth Leffel, et al.
The Journal of Infectious Diseases|November 8, 2017
Drivers of Tuberculosis TransmissionBarun Mathema, Jason R Andrews, Ted Cohen, et al.
Antimicrobial Agents and Chemotherapy|March 14, 2012
Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelinesHelen McIlleron, Roxana Rustomjee, Mahnaz Vahedi, et al.
The Journal of Infectious Diseases|November 8, 2017
Research Roadmap for Tuberculosis Transmission Science: Where Do We Go From Here and How Will We Know When We're There?Sara C Auld, Anne G Kasmar, David W Dowdy, et al.
Plos One|May 19, 2012
Effect of standard tuberculosis treatment on plasma cytokine levels in patients with active pulmonary tuberculosisCatherine Riou, Blas Perez Peixoto, Lindi Roberts, et al.
American Journal of Respiratory and Critical Care Medicine|April 5, 2005
The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosisFrik A Sirgel, P Bernard Fourie, Peter R Donald, et al.
The Lancet. Infectious Diseases|December 18, 2018
Advances in the understanding of Mycobacterium tuberculosis transmission in HIV-endemic settingsJulian S Peters, Jason R Andrews, Mark Hatherill, et al.
The Lancet. Infectious Diseases|April 3, 2016
Tuberculosis--advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkersRobert S Wallis, Markus Maeurer, Peter Mwaba, et al.
Pageof 5